Clinical trials: Infliximab, completed
Inflammatory Bowel Diseases
The Impact of Medication Belief on Adherence to Infliximab in Patients With Crohn's Disease
The IFX adherence to CD in China was not high. Medicine concerns may be predictive factor of adherence. By enhancing knowledge and relieving medicine concerns, we may increase patients' adherence to IFX.
- Trial name
- NCT05777616
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Crohn's Disease, Inflammatory Bowel Disease
GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )
This study will be a multicentre prospective randomized trial to assess the percentage of patients with IBD who, after stopping anti-TNF treatment, have sustained clinical remission at one year compared to those in which the…
- Conditions
- Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis
- Trial name
- NCT02994836
- Testing
- Anti-TNF: Infliximab (Infusion), Anti-TNF discontinuation: Physiological saline solution, Anti-TNF:Adalimumab (Subcutaneus)
- Where
- Spain
- Volunteers
- 139 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Rheumatoid Arthritis
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
This is a Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between CT-P13 SC and CT-P13 IV in Patients with Active Rheumatoid Arthritis (RA).
- Trial name
- NCT03147248
- Testing
- CT-P13
- Where
- South Korea
- Volunteers
- 407 people
- Sponsor
- Celltrion
Psoriasis
A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)
Subjects with moderate-to-severe chronic psoriasis not responding to standard or biologic therapy will be eligible to enroll in this study.
- Trial name
- ESAQUALITY (NCT00687401)
- Testing
- Infliximab
- Volunteers
- 215 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease, Protein Metabolism
Protein and Energy Metabolism in Pediatric Crohn's Disease
The metabolic response to Crohn's disease, including increased proteolysis and lipolysis and changes in energy expenditure, plays a significant role in the resulting malnutrition from which these patients suffer.
- Conditions
- Crohn's Disease, Protein Metabolism, Energy Metabolism
- Trial name
- NCT00583232
- Testing
- Stable isotope infusions
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Acute Graft-versus-host Disease
Infliximab Efficacy in Relation to Therapeutic Drug Monitoring and Serum TNFα Levels in Pediatric HSCT
Despite significant progress in overall survival and event-free survival in Pediatric Hematopoietic Stem Cell Transplant (HSCT), therapeutic options for graft-versus-host disease control remain limited, particularly in…
- Trial name
- NCT05825833
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- IRCCS Burlo Garofolo
Arthritis, Rheumatoid
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
The purpose of this study is to compare the proportion of patients with an infusion reaction in Rheumatoid arthritis (RA) patients treated with Golimumab Intravenous (IV) or Infliximab.
- Trial name
- AWARE (NCT02728934)
- Testing
- Golimumab Intravenous (IV), Infliximab, Biosimilar Infliximab
- Where
- 85 sites in United States
- Volunteers
- 1,279 people
- Sponsor
- Janssen Scientific Affairs, LLC
Rheumatoid Arthritis
Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents
To compare the proportion of rheumatoid arthritis (RA) patients prescribed opioids, benzodiazepines, and antidepressants before versus after starting each of the following biologics: abatacept, infliximab, etanercept, adalimumab…
- Trial name
- NCT01137838
- Volunteers
- 1,810 people
- Sponsor
- Bristol-Myers Squibb
Ankylosing Spondylitis
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.
- Trial name
- NCT01220518
- Testing
- Infliximab
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Celltrion
Fatigue, Inflammatory Bowel Disease
Metabolomic Markers of Fatigue in Inflammatory Bowel Disease
Fatigue is a common symptom and a leading concern in patients with inflammatory bowel disease (IBD) and often persists despite clinical and endoscopic remission.
- Conditions
- Fatigue, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT04191707
- Volunteers
- 18 people
- Sponsor
- Corporacion Parc Tauli
Juvenile Idiopathic Arthritis
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis
The objective of this study is to compare in very early polyarticular juvenile idiopathic arthritis (JIA) the efficacy, safety, and cost-benefit-ratio of three treatment strategies: biologic combination, combination of…
- Trial name
- ACUTE-JIA (NCT01015547)
- Testing
- Infliximab plus methotrexate, Combination of DMARDs, Methotrexate alone
- Where
- 6 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Helsinki University Central Hospital
Rheumatoid Arthritis
RHYTHM (Formerly Escape II Myocardium)
For aim 1, the proposed studies will be performed in 150 patients with RA and 25 subjects without RA (healthy volunteers) who will function as controls.
- Trial name
- RHYTHM (NCT01548768)
- Testing
- TNF inhibitors, DMARDs
- Where
- United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Columbia University
Ulcerative Colitis
Efficacy of Golimumab in Maintaining Deep Remission in UC Patients in Prolonged Remission With Infliximab
This study monitors the efficacy and safety of Golimumab in maintaining deep remission and quality of life in Ulcerative Colitis patients in deep prolonged remission with Infliximab.
- Trial name
- Switch (NCT02868398)
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Evangelismos Hospital
Pediatric Ulcerative Colitis
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis
The purpose of this study is to evaluate the the efficacy of TA-650 using Clinical activity index (CAI) score and other evaluation indicators in pediatric patients with moderate to severe ulcerative colitis after TA-650…
- Trial name
- NCT01585155
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Tanabe Pharma Corporation
Psoriasis
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns…
- Trial name
- NCT05320159
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 17,743 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)
The Swefot trial was designed to compare two treatment strategies for patients with early rheumatoid arthritis (less than 1 year symptom duration): the use of a combination of traditional antirheumatic medications (DMARDs)…
- Trial name
- SWEFOT (NCT00764725)
- Testing
- conventional DMARD combination, MTX plus anti-TNF
- Volunteers
- 487 people
- Sponsor
- Karolinska Institutet
IBD, Infliximab
Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease
The aim of this study is to evaluate the IFX exposure (AUC), effectiveness, presence of ADAbs and treatment burden before and after switching from IV to SC IFX maintenance treatment in a real-world cohort of IBD patients with…
- Conditions
- IBD, Infliximab, Crohn Disease, Ulcerative Colitis
- Trial name
- SHUFFLE (NCT06381518)
- Testing
- Switch to SC CT-P13.
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Zuyderland Medisch Centrum
Arthritis, Psoriatic
A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis
The purpose of this study is to determine if Infliximab is safe and effective in the treatment of psoriatic arthritis. Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of…
- Trial name
- NCT00051623
- Testing
- Infliximab
- Volunteers
- 70 people
- Sponsor
- Centocor, Inc.
Inflammatory Bowel Diseases, Crohn Disease
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNFα (infliximab, adalimumab or golimumab), vedolizumab, ustekinumab and tofacitinib will be made…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- BioIBD (NCT03885713)
- Testing
- Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
- Where
- 21 sites in Spain
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Ankylosing Spondylitis
Study of Two Schedules of Infliximab Maintenance Therapy in Ankylosing Spondylitis
Continuous treatment with the anti-tumor necrosis factor alpha monoclonal antibody infliximab is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation results in disease relapse, with variable delay.
- Trial name
- NCT00439283
- Testing
- infliximab, methotrexate
- Where
- 31 sites in France
- Volunteers
- 240 people
- Sponsor
- Association de Recherche Clinique en Rhumatologie